nach oben

Current Colorectal Cancer Reports

Erschienen in:

01.09.2013 | Therapeutic Approaches to Metastatic Colorectal Cancers (E Díaz-Rubio, Section Editor)

Role of Chemotherapy in Peritoneal Carcinomatosis in Metastatic Colorectal Cancer

verfasst von: Jan Franko, Charles D. Goldman, Kiran K. Turaga

Erschienen in: Current Colorectal Cancer Reports | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Peritoneal carcinomatosis from colorectal cancer is increasingly recognized as a special form of metastatic disease. This review focuses on the efficacy of systemic chemotherapy in the setting of peritoneal carcinomatosis. Peritoneal carcinomatosis-affected individuals succumb to their disease earlier than those without known carcinomatosis, with an approximately 30 % reduction in overall survival. Modern cytotoxic combination chemotherapy incorporating oxaliplatin and irinotecan has resulted in marked improvement of overall survival among carcinomatosis patients, but not to the same extent as for non-carcinomatosis patients. Biologicals are also associated with increased overall survival, but still seem to underperform in the carcinomatosis patient. Efficacy of 5FU monotherapy seems negligible. Evidence suggests future trials should be stratified by peritoneal carcinomatosis status. Complementary benefits of systemic chemotherapy and cytoreductive surgical approaches warrant further studies.

Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–45. doi:10.1002/ijc.27711.PubMedCrossRef

Varghese S, Burness M, Xu H, Beresnev T, Pingpank J, Alexander HR. Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. Ann Surg Oncol. 2007;14(12):3460–71. doi:10.1245/s10434-007-9557-7.PubMedCrossRef

Levine EA, Blazer 3rd DG, Kim MK, Shen P, Stewart JH, Guy C, et al. Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg. 2012;214(4):599–606. doi:10.1016/j.jamcollsurg.2011.12.028. discussion −7.PubMedCrossRef

Blair SL, Chu DZ, Schwarz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol. 2001;8(8):632–7.PubMedCrossRef

Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63. doi:10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O.PubMedCrossRef

Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221(2):124–32.PubMedCrossRef

•• Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43. doi:10.1200/JCO.2003.04.187. First and only completed randomized trail focusing on patients with isolated peritoneal carcinomatosis—comparing best systemic chemotherapy available at that time (5FU, minority patients also irinotecan) with or without cytoreductive surgery plus intraperitoneal chemotherapy. Patients randomized to systemic chemotherapy plus cytoreduction survived longer on intention-to-treat analysis (HR = 0.55).PubMedCrossRef

Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681–5. doi:10.1200/JCO.2008.19.7160.PubMedCrossRef

Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh 3rd HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756–62. doi:10.1002/cncr.25116.PubMedCrossRef

10.

•• Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30(3):263–7. doi:10.1200/JCO.2011.37.1039. Largest available secondary analysis of systemic chemotherapy trials with attention to peritoneal carcinomatosis. Patients with peritoneal carcinomatosis benefited from systemic chemotherapy, but survived shorter (HR = 1.4).PubMedCrossRef

11.

Pelz JO, Chua TC, Esquivel J, Stojadinovic A, Doerfer J, Morris DL, et al. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer. 2010;10:689. doi:10.1186/1471-2407-10-689.PubMedCrossRef

12.

Pelz JO, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99(1):9–15. doi:10.1002/jso.21169.PubMedCrossRef

13.

Khattak MA, Martin HL, Beeke C, Price T, Carruthers S, Kim S, et al. Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer. 2012;11(4):247–54. doi:10.1016/j.clcc.2012.06.004.PubMedCrossRef

14.

Assersohn L, Norman A, Cunningham D, Benepal T, Ross PJ, Oates J. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer. 1999;79(11–12):1800–5. doi:10.1038/sj.bjc.6690287.PubMed

15.

•• Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38(7):617–23. doi:10.1016/j.ejso.2012.03.008. European secondary analysis of systemic chemotherapy trials with attention to peritoneal carcinomatosis. Patients with peritoneal carcinomatosis benefited from systemic chemotherapy, but survived shorter. Outcomes were comparable with those in North American study in Ref. [10].PubMedCrossRef

16.

• Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99(5):699–705. doi:10.1002/bjs.8679. Detailed analysis of peritoneal carcinomatosis incidence and development after diagnosis of any stage CRC in population.PubMedCrossRef

17.

Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545–50. doi:10.1046/j.1365-2168.2002.02274.x.PubMedCrossRef

18.

Kerscher AG, Chua TC, Gasser M, Maeder U, Kunzmann V, Isbert C, Germer CT, Pelz JO. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer. 2013;108(7):1432–9. doi:10.1038/bjc.2013.82.

19.

• Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128(11):2717–25. doi:10.1002/ijc.25596. Detailed analysis of peritoneal carcinomatosis outcomes in defined population and changes over time. Peritoneal carcinomatosis was associated with poorer outcome.PubMedCrossRef

20.

Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol. 2005;12(10):765–77.

21.

Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011;104(5):856–62. doi:10.1038/bjc.2011.19.PubMedCrossRef

22.

Helyer LK, Law CH, Butler M, Last LD, Smith AJ, Wright FC. Surgery as a bridge to palliative chemotherapy in patients with malignant bowel obstruction from colorectal cancer. Ann Surg Oncol. 2007;14(4):1264–71. doi:10.1245/s10434-006-9303-6.PubMedCrossRef

23.

Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.PubMedCrossRef

24.

Gilly FN, Carry PY, Sayag AC, Brachet A, Panteix G, Salle B, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology. 1994;41(2):124–9.PubMed

25.

Klaver YL, Lemmens VE, Creemers GJ, Rutten HJ, Nienhuijs SW, de Hingh IH. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol. 2011;22(10):2250–6. doi:10.1093/annonc/mdq762.PubMedCrossRef

26.

• Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13(2):308–17. Detailed analysis of efficacy of 5FU chemotherapy in mCRC demonstrating significant outcome variability. Information on peritoneal carcinomatosis was missing among 30 % cases, but peritoneal carcinomatosis was associated with poorer outcome.PubMedCrossRef

27.

Folprecht G, Köhne C-H, Lutz M. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. In: Ceelen WP, editor. Peritoneal carcinomatosis: a multidisciplinary approach. Cancer treatment and research, vol 134: Springer, New York; 2007. p. 425–40.

28.

Zani S, Papalezova K, Stinnett S, Tyler D, Hsu D, Blazer 3rd DG. Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. J Surg Oncol. 2012. doi:10.1002/jso.23222.PubMed

29.

Lee DH, Oh SY, Lee YR, Huh SJ, Yoon HH, Kim SH, et al. A phase II study of modified FOLFOX4 for colorectal cancer patients with peritoneal carcinomatosis. Cancer Res Treat. 2011;43(4):225–30. doi:10.4143/crt.2011.43.4.225.PubMedCrossRef

30.

Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol. 2005;23(36):9441–2. doi:10.1200/JCO.2005.04.479.PubMedCrossRef

31.

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37. doi:10.1200/JCO.2004.05.113.PubMedCrossRef

32.

Chua TC, Morris DL, Saxena A, Esquivel J, Liauw W, Doerfer J, et al. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol. 2011;18(6):1560–7. doi:10.1245/s10434-010-1522-1.PubMedCrossRef

33.

Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63(2):364–7.PubMedCrossRef

34.

Köhne C-H, Bokemeyer C, Folprecht G, Sartorius U, Schlichting M, Rougier PR et al. Cetuximab plus chemotherapy in patients with liver-limited or non-liver-limited KRAS wild-type colorectal metastases: a pooled analysis of the CRYSTAL and OPUS studies. J Clin Oncol. 2012;30(suppl 4):abstr 96.

35.

Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702–13. doi:10.1245/s10434-007-9487-4.PubMedCrossRef

36.

Fajardo AD, Tan B, Reddy R, Fleshman J. Delayed repeated intraperitoneal chemotherapy after cytoreductive surgery for colorectal and appendiceal carcinomatosis. Dis Colon Rectum. 2012;55(10):1044–52. doi:10.1097/DCR.0b013e318265ad42.PubMedCrossRef

37.

Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92. doi:10.1200/JCO.2004.10.012.PubMedCrossRef

38.

Vaillant JC, Nordlinger B, Deuffic S, Arnaud JP, Pelissier E, Favre JP, et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: a multicenter phase III trial. Ann Surg. 2000;231(4):449–56.PubMedCrossRef

39.

Nordlinger B, Rougier P, Arnaud JP, Debois M, Wils J, Ollier JC, et al. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. Lancet Oncol. 2005;6(7):459–68. doi:10.1016/S1470-2045(05)70222-9.PubMedCrossRef

40.

Ceelen WP, Bracke ME. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol. 2009;10(1):72–9. doi:10.1016/S1470-2045(08)70335-8.PubMedCrossRef

41.

Pelz JO, Doerfer J, Dimmler A, Hohenberger W, Meyer T. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations. BMC Cancer. 2006;6:162. doi:10.1186/1471-2407-6-162.PubMedCrossRef

42.

Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11(2):178–86.PubMedCrossRef

43.

Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic Intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32. doi:10.1245/s10434-008-9966-2.PubMedCrossRef

44.

Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist. 2005;10(2):112–22. doi:10.1634/theoncologist.10-2-112.PubMedCrossRef

45.

Elias D, Goere D, Blot F, Billard V, Pocard M, Kohneh-Shahri N, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14(6):1818–24. doi:10.1245/s10434-007-9348-1.PubMedCrossRef

46.

Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–21. doi:10.1002/ijc.25423.PubMedCrossRef

Titel: Role of Chemotherapy in Peritoneal Carcinomatosis in Metastatic Colorectal Cancer
verfasst von: Jan Franko
Charles D. Goldman
Kiran K. Turaga
Publikationsdatum: 01.09.2013
Verlag: Springer US
Erschienen in: Current Colorectal Cancer Reports / Ausgabe 3/2013
Print ISSN: 1556-3790
Elektronische ISSN: 1556-3804
DOI: https://doi.org/10.1007/s11888-013-0173-6

Springer Medizin

Role of Chemotherapy in Peritoneal Carcinomatosis in Metastatic Colorectal Cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Animal Models to Test Adjuvant Treatment: An Experimental Model of Colon Cancer

The Continuum of Care in Chemotherapy Approach to Metastatic Colorectal Cancer

The Role of Adjuvant Therapy in the Elderly

Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer

Clinical Reasons for Initiation of Adjuvant Phase III Trials on Colon Cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie